The stock has a 36-month beta value of 0.33. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.”
The public float for RAPT is 31.00M, and at present, short sellers hold a 10.13% of that float. On October 22, 2024, the average trading volume of RAPT was 275.44K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RAPT) stock’s latest price update
The stock price of RAPT Therapeutics Inc (NASDAQ: RAPT) has plunged by -8.10 when compared to previous closing price of 1.79, but the company has seen a -14.77% decline in its stock price over the last five trading sessions. zacks.com reported 2024-06-14 that Rapt Therapeutics (RAPT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RAPT’s Market Performance
RAPT Therapeutics Inc (RAPT) has experienced a -14.77% fall in stock performance for the past week, with a -8.10% drop in the past month, and a -46.07% drop in the past quarter. The volatility ratio for the week is 7.04%, and the volatility levels for the past 30 days are at 9.97% for RAPT. The simple moving average for the last 20 days is -11.52% for RAPT stock, with a simple moving average of -78.67% for the last 200 days.
Analysts’ Opinion of RAPT
Barclays gave a rating of “Equal Weight” to RAPT, setting the target price at $4 in the report published on May 10th of the current year.
RAPT Trading at -18.24% from the 50-Day Moving Average
After a stumble in the market that brought RAPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.99% of loss for the given period.
Volatility was left at 9.97%, however, over the last 30 days, the volatility rate increased by 7.04%, as shares sank -6.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.53% lower at present.
During the last 5 trading sessions, RAPT fell by -14.77%, which changed the moving average for the period of 200-days by -92.99% in comparison to the 20-day moving average, which settled at $1.8592. In addition, RAPT Therapeutics Inc saw -93.38% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RAPT starting from Brockstedt Dirk G., who sale 898 shares at the price of $22.78 back on Jan 05 ’24. After this action, Brockstedt Dirk G. now owns 27,820 shares of RAPT Therapeutics Inc, valued at $20,456 using the latest closing price.
HO WILLIAM, the Chief Medical Officer of RAPT Therapeutics Inc, sale 2,500 shares at $21.68 during a trade that took place back on Dec 21 ’23, which means that HO WILLIAM is holding 15,020 shares at $54,200 based on the most recent closing price.
Stock Fundamentals for RAPT
Current profitability levels for the company are sitting at:
- -24.39 for the present operating margin
- 0.65 for the gross margin
The net margin for RAPT Therapeutics Inc stands at -22.77. The total capital return value is set at -1.15. Equity return is now at value -77.97, with -69.23 for asset returns.
Based on RAPT Therapeutics Inc (RAPT), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at -18.31. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -56.3.
Currently, EBITDA for the company is -125.85 million with net debt to EBITDA at 0.24. When we switch over and look at the enterprise to sales, we see a ratio of 4.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.14.
Conclusion
To sum up, RAPT Therapeutics Inc (RAPT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
